Literature DB >> 8162056

Mutation detection in the X-linked agammaglobulinemia gene, BTK, using single strand conformation polymorphism analysis.

L A Bradley1, A K Sweatman, R C Lovering, A M Jones, G Morgan, R J Levinsky, C Kinnon.   

Abstract

The gene defective in X-linked agammaglobulinemia (XLA) has recently been isolated and identified as btk, a non-receptor protein tyrosine kinase. We have utilized the technique of single strand conformation polymorphism (SSCP) analysis for the btk gene to identify mutations in XLA patients. The btk gene in affected boys from 10 families was analysed and mutations were identified in eight cases; seven of these were point mutations and one was a small insertion. The mutations were found throughout the gene coding region. Six of the patients have classical XLA and two have less severe forms of the disease. We have also identified a polymorphism at nucleotide position 2031. This technique will allow us to provide more accurate diagnoses of the disease and to determine the nature of the functional defects in the btk gene in these families.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162056     DOI: 10.1093/hmg/3.1.79

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  30 in total

1.  B-cell-specific demethylation of BTK, the defective gene in X-linked agammaglobulinemia.

Authors:  O Parolini; J Rohrer; L H Shapiro; M E Conley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

2.  Discordant phenotype in siblings with X-linked agammaglobulinemia.

Authors:  M J Bykowsky; R N Haire; Y Ohta; H Tang; S S Sung; E S Veksler; J M Greene; S M Fu; G W Litman; K E Sullivan
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

3.  X linked agammaglobulinaemia with a 'leaky' phenotype.

Authors:  A Jones; L Bradley; L Alterman; M Tarlow; R Thompson; C Kinnon; G Morgan
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

4.  Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA.

Authors:  H B Gaspar; T Lester; R J Levinsky; C Kinnon
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

5.  Assessment of male CVID patients for mutations in the Btk gene: how many have been misdiagnosed?

Authors:  S A Weston; M L Prasad; C G Mullighan; H Chapel; E M Benson
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

6.  Identification of deletions in the btk gene allows unambiguous assessment of carrier status in families with X-linked agammaglobulinaemia.

Authors:  R C Lovering; A Sweatman; S A Genet; H R Middleton-Price; D Vetrie; I Vorechovsky; D Bentley; G Fontan; T Español; G Morgan
Journal:  Hum Genet       Date:  1994-07       Impact factor: 4.132

7.  Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.

Authors:  M Vihinen; D Vetrie; H S Maniar; H D Ochs; Q Zhu; I Vorechovský; A D Webster; L D Notarangelo; L Nilsson; J M Sowadski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 8.  Role of PIR-B in autoimmune glomerulonephritis.

Authors:  Toshiyuki Takai; Akira Nakamura; Shota Endo
Journal:  J Biomed Biotechnol       Date:  2010-10-04

9.  Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis.

Authors:  P A Clark; T Lester; S Genet; A M Jones; R Hendriks; R J Levinsky; C Kinnon
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

10.  Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.

Authors:  Y Ohta; R N Haire; R T Litman; S M Fu; R P Nelson; J Kratz; S J Kornfeld; M de la Morena; R A Good; G W Litman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.